Raymond James Reiterates Buy Rating on Tonix Pharmaceuticals
Raymond James maintains its buy rating on Tonix Pharmaceuticals with a $26 price target, a 96.67% upside from the current price.
Key Points
- Raymond James reiterated its buy rating on Tonix Pharmaceuticals (TNXP) with a target price of $26 on June 25, 2026.
- Raymond James's $26 price target implies 96.67% upside from Tonix Pharmaceuticals Holding Corp.'s ($TNXP) current $13.22 share price.
- Shares of TNXP traded near $12.1 on Thursday, with a market cap of about $194.5 million and a 52-week range of $10.03 to $69.97.
- Insider buying activity includes CEO Seth Lederman purchasing 5,000 shares at $11.79 each on June 9, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Raymond James reiterated its buy rating on Tonix Pharmaceuticals Holding Corp. (NasdaqGS: TNXP) on June 25, 2026. Analyst Tiago Fauth set a price target of $26 for the company. This follows a period of notable insider buying activity, reflecting a positive outlook.
Raymond James vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Tonix Pharmaceuticals Holding Corp. Stock Down 2.7%
Shares of Tonix Pharmaceuticals traded near $12.1 on Thursday. The company has a market cap of approximately $194.5 million. Tonix operates in the biotechnology industry, focusing on therapies for central nervous system disorders and other areas. The stock's 52-week range is between $10.03 and $69.97, and it has a beta of 1.679, indicating higher volatility compared to the market.
$TNXP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Tonix Pharmaceuticals Holding Corp.
Recent insider transactions at Tonix Pharmaceuticals show a series of purchases. On June 12, 2026, Carolyn Taylor bought 1,415 shares at $10.55 each. Earlier, on June 9, 2026, CEO Dr. Seth Lederman acquired 5,000 shares at an average price of $11.79. Richard Newcomb Stillwell also bought 5,000 shares on June 8, 2026, at $11.65 each. These transactions suggest confidence in the company's future.
Analysts Set New Price Targets
On June 25, 2026, Raymond James reiterated its buy rating with a $26 price target. Previously, on May 4, 2026, TD Cowen initiated coverage with a buy rating and a $22 target. The overall analyst consensus for Tonix Pharmaceuticals is a strong buy, with an average target price of $46.25 from four analyst opinions.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company based in Berkeley Heights, New Jersey. It develops and commercializes therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Founded in 2007, the company is led by CEO Dr. Seth Lederman and employs around 142 people. Tonix is working on a range of treatments, including those for fibromyalgia, migraines, and various autoimmune and infectious diseases.
Bottom Line
Raymond James's reiteration of its buy rating with a $26 target highlights confidence in Tonix Pharmaceuticals' potential. The stock's recent trading activity and insider purchases suggest positive sentiment around the company's prospects. Investors often track such developments to gauge market sentiment, though it's worth noting that analyst ratings and insider activity are just parts of the broader investment picture.
Get Tonix Pharmaceuticals Holding Corp. alerts
New 13F filings, insider trades, and analyst moves on $TNXP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.